Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of QVA149 vs Umeclidinium/Vilanterol in COPD
NCT02487446Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Jul 2015; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02487446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487446.